<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04052516</url>
  </required_header>
  <id_info>
    <org_study_id>NST-02</org_study_id>
    <nct_id>NCT04052516</nct_id>
  </id_info>
  <brief_title>A Phase 2b Study of Icosabutate in Fatty Liver Disease</brief_title>
  <acronym>ICONA</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of NST-4016 in Patients With Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NorthSea Therapeutics B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NorthSea Therapeutics B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2b study to evaluate the efficacy of different doses of NST-4016 on the resolution of
      NASH without worsening of fibrosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 62 week (including screening and follow-up), multicenter, randomized, double blind,
      placebo-controlled, parallel group study in male and female patients with a histological
      diagnosis of NASH. The study includes a screening period, double blind treatment period, and
      post-treatment follow up
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Anticipated">September 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 5, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of patients with resolution of NASH, defined as disappearance of ballooning (score = 0) with lobular inflammation score 0 or 1, with no worsening of fibrosis.</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Nonalcoholic fatty liver disease (NAFLD) activity score (NAS)</measure>
    <time_frame>52 weeks</time_frame>
    <description>A histological scoring system that assesses a liver biopsy and gives scores for steatosis (0-3), lobular inflammation (0-3), and hepatocyte ballooning (0-2) giving a total score of (0-8). The higher the score the more severe the disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in individual histological scores for steatosis, ballooning, inflammation, and fibrosis from baseline</measure>
    <time_frame>52 weeks</time_frame>
    <description>Changes in scores for the individual component parts of the Nonalcoholic fatty liver disease (NAFLD) activity score (NAS) as judged by a pathologist examining sections from a liver biopsy; steatosis (range 0-3), lobular inflammation (range 0-3), and hepatocyte ballooning (range 0-2) In all cases a higher number denotes more severe disease activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the liver enzymes Aspartate Aminotransferase (AST)U/L, Alanine Aminotransferase ( ALT)U/L and Gamma Glutamyl Transferase (GGT) U/L from baseline</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bilirubin mg/dL from baseline</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Non Alcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral capsules taken one daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Icosabutate 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Icosabutate 300mg oral capsule taken once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Icosabutate 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Icosabutate 600mg oral capsules taken once daily for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icosabutate</intervention_name>
    <description>Icosabutate oral capsule once daily</description>
    <arm_group_label>Icosabutate 300mg</arm_group_label>
    <arm_group_label>Icosabutate 600mg</arm_group_label>
    <other_name>NST-4016</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo oral capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provides signed written informed consent and agrees to comply with the study protocol.

          -  Is a male or female aged 18 to 75 years, inclusive.

          -  Has a histological diagnosis of NASH prior to study entry

          -  Has (NAS) greater than or equal to 4, with a score of at least 1 in each component
             (steatosis, lobular inflammation, and ballooning),

          -  Has a fibrosis score F1 to F3, inclusive (F1 capped at 30%),

          -  Has a Proton Density Fat Fraction (PDFF) greater than or equal to 10% on MRI at
             screening

        Exclusion Criteria:

          -  Has a known history of alcohol abuse or daily heavy alcohol consumption

          -  Has had bariatric surgery within the past 5 years

          -  Has significant systemic or major illnesses other than liver disease

          -  Has a recent (within 6 months) history of cardiac dysrhythmias and/or cardiovascular
             disease

          -  Has uncontrolled arterial hypertension

          -  Positive for Hep B, Hepatitis C Virus (HCV) or HCV Polymerase Chain Reaction (PCR)

          -  Has type 1 diabetes mellitus

          -  Has diabetic ketoacidosis

          -  Has a history of liver decompensation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trial Manager</last_name>
    <phone>1.800.730.5779</phone>
    <email>icona@medpace.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Central ResearchAssociates Inc.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Liver Health</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Liver Health - Glendale</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Liver Health</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Adobe Clinical Research, LLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arkansas Gastroenterology - North Little Rock</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fresno Clinical Research Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Huntington Park</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Wilshire</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Panorama</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Santa Ana</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Denver Gastroenterology</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
    </contact>
    <contact_backup>
      <last_name>icona@medpace.com</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Excel Medical Clinical Trials, LLC</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33434</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Research Institute</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Covenant Research LLC</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Specialists of Georgia PC</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consultants</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Associates, PA</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manger</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Therapy and Advanced Research LLC</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cumberland Research Associates, LLC</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aventiv Research, Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Premier Research</name>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <zip>37040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastro One</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinicl Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consultants</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Texas Research Institute</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liver Associates of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icon@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Doctors Hospital at Renaissance, LLC</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quality Research Inc</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consultants - Webster</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunter Holmes McGuire VA Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>800-730-5779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion de Investigacion (FDI)</name>
      <address>
        <city>San Juan</city>
        <zip>00927-4807</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Manager</last_name>
      <phone>18007305779</phone>
      <email>icona@medpace.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 7, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

